129 related articles for article (PubMed ID: 22202179)
1. Chemokines and cytokines in patients with an occult Onchocerca volvulus infection.
Lechner CJ; Gantin RG; Seeger T; Sarnecka A; Portillo J; Schulz-Key H; Karabou PK; Helling-Giese G; Heuschkel C; Banla M; Soboslay PT
Microbes Infect; 2012 May; 14(5):438-46. PubMed ID: 22202179
[TBL] [Abstract][Full Text] [Related]
2. Chemokines in onchocerciasis patients after a single dose of ivermectin.
Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
[TBL] [Abstract][Full Text] [Related]
3. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
Mai CS; Hamm DM; Banla M; Agossou A; Schulz-Key H; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2007 Mar; 147(3):504-12. PubMed ID: 17302900
[TBL] [Abstract][Full Text] [Related]
4. Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.
Johanns SI; Gantin RG; Wangala B; Komlan K; Halatoko WA; Banla M; Karabou P; Luty AJ; Schulz-Key H; Köhler C; Soboslay PT
PLoS Negl Trop Dis; 2022 May; 16(5):e0010340. PubMed ID: 35503786
[TBL] [Abstract][Full Text] [Related]
5. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
Soboslay PT; Geiger SM; Weiss N; Banla M; Lüder CG; Dreweck CM; Batchassi E; Boatin BA; Stadler A; Schulz-Key H
Immunology; 1997 Apr; 90(4):592-9. PubMed ID: 9176114
[TBL] [Abstract][Full Text] [Related]
6. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.
Soboslay PT; Lüder CG; Hoffmann WH; Michaelis I; Helling G; Heuschkel C; Dreweck CM; Blanke CH; Pritze S; Banla M
Clin Exp Immunol; 1994 May; 96(2):238-44. PubMed ID: 8187332
[TBL] [Abstract][Full Text] [Related]
7. Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis.
Cooper PJ; Beck LA; Espinel I; Deyampert NM; Hartnell A; Jose PJ; Paredes W; Guderian RH; Nutman TB
Clin Immunol; 2000 Apr; 95(1 Pt 1):51-61. PubMed ID: 10794432
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and chemokine responses in adults, newborns and children exposed to Entamoeba histolytica/dispar, Onchocerca volvulus and Plasmodium falciparum.
Kocherscheidt L; Agossou A; Gantin RG; Hamm DM; Banla M; Soboslay PT
Pediatr Allergy Immunol; 2010 Jun; 21(4 Pt 2):e756-63. PubMed ID: 20408971
[TBL] [Abstract][Full Text] [Related]
9. Prenatal immune priming in onchocerciasis-onchocerca volvulus-specific cellular responsiveness and cytokine production in newborns from infected mothers.
Soboslay PT; Geiger SM; Drabner B; Banla M; Batchassi E; Kowu LA; Stadler A; Schulz-Key H
Clin Exp Immunol; 1999 Jul; 117(1):130-7. PubMed ID: 10403926
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from Cameroon.
Pion SD; Nana-Djeunga HC; Kamgno J; Tendongfor N; Wanji S; Njiokou F; Prichard RK; Boussinesq M
PLoS Negl Trop Dis; 2013; 7(2):e2084. PubMed ID: 23469307
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulation in onchocerciasis: predominance of Th1-type responsiveness to low molecular weight antigens of Onchocerca volvulus in exposed individuals without microfilaridermia and clinical disease.
Lüder CG; Schulz-Key H; Banla M; Pritze S; Soboslay PT
Clin Exp Immunol; 1996 Aug; 105(2):245-53. PubMed ID: 8706329
[TBL] [Abstract][Full Text] [Related]
12. Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin.
Akuffo H; Maasho K; Lavebratt C; Engström K; Britton S
Clin Exp Immunol; 1996 Feb; 103(2):244-52. PubMed ID: 8565307
[TBL] [Abstract][Full Text] [Related]
13. Immunoepidemiological profiling of onchocerciasis patients reveals associations with microfilaria loads and ivermectin intake on both individual and community levels.
Arndts K; Specht S; Debrah AY; Tamarozzi F; Klarmann Schulz U; Mand S; Batsa L; Kwarteng A; Taylor M; Adjei O; Martin C; Layland LE; Hoerauf A
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2679. PubMed ID: 24587458
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an Onchocerca ochengi microfilarial hamster model for onchocerciasis drug screens.
Mbah GE; Ayiseh RB; Cho-Ngwa F
BMC Infect Dis; 2016 Aug; 16(1):404. PubMed ID: 27515037
[TBL] [Abstract][Full Text] [Related]
15. Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naïve and a frequently treated population from Cameroon.
Nana-Djeunga HC; Bourguinat C; Pion SD; Bopda J; Kengne-Ouafo JA; Njiokou F; Prichard RK; Wanji S; Kamgno J; Boussinesq M
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2824. PubMed ID: 24762816
[TBL] [Abstract][Full Text] [Related]
16. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo.
Tagboto SK; Townson S
Ann Trop Med Parasitol; 1996 Oct; 90(5):497-505. PubMed ID: 8915126
[TBL] [Abstract][Full Text] [Related]
17. Reductions in microfilaridermia by repeated ivermectin treatment are associated with lower Plasmodium-specific Th17 immune responses in Onchocerca volvulus-infected individuals.
Arndts K; Klarmann-Schulz U; Batsa L; Debrah AY; Epp C; Fimmers R; Specht S; Layland LE; Hoerauf A
Parasit Vectors; 2015 Mar; 8():184. PubMed ID: 25889652
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of antibodies to onchocerca volvulus in residents of Oaxaca, Mexico, treated for 10 years with ivermectin.
Gómez-Priego A; Mendoza R; de-la-Rosa JL
Clin Diagn Lab Immunol; 2005 Jan; 12(1):40-3. PubMed ID: 15642982
[TBL] [Abstract][Full Text] [Related]
19. Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density.
Brattig NW; Lepping B; Timmann C; Büttner DW; Marfo Y; Hamelmann C; Horstmann RD
J Infect Dis; 2002 Apr; 185(8):1148-54. PubMed ID: 11930325
[TBL] [Abstract][Full Text] [Related]
20. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin.
Fischer P; Kipp W; Kabwa P; Buttner DW
Am J Trop Med Hyg; 1995 Aug; 53(2):171-8. PubMed ID: 7677220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
